Study of asciminib in adults with Ph+ CML on Scemblix
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at using asciminib in people with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) who are taking Scemblix. If you already use Scemblix, the study may test whether switching or adding asciminib is safe and helpful for managing your leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) with Ph+ chronic myeloid leukemia (CML)
- You are currently taking, or will soon take, Scemblix according to your local approved label
- You agree to sign written informed consent before joining the study
- You do not have any Scemblix-related contraindication (a medical reason you can’t take it) listed in your local label
- You will not take any investigational (research) medicines during the observation period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study looks at the safety and effects of the drug asciminib in young adults (18 and older) with a type of leukemia called chronic myeloid leukemia (CML). It uses information already collected from patients' medical records to see how well the drug works and how safe it is.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study follows real-world patients who are taking a medicine called asciminib for chronic myeloid leukemia (a blood cancer) after their first treatment didn't work or stopped working. Researchers want to see how well asciminib actually helps patients in everyday practice.
This study looks at how well the medicine Scemblix (asciminib) works for people in China who have just been diagnosed with a certain type of leukemia (chronic myeloid leukemia in chronic phase). It aims to see if starting this treatment soon after diagnosis is effective and safe.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.